Cancer cell-dependent increase in senescence-like populations following exosome treatment from bone marrow and induced pluripotent stem cell-derived mesenchymal stem cells

Figure 4 Senescence induction in PANC1 and MDA-MB-231 cells following treatment with exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells and bone marrow mesenchymal stem cells. A: Representative images of senescence-associated beta-galactosidase (SA-βGal)-stained PANC1 cells after 48 hours of treatment. Blue staining marks SA-βGal-positive senescent cells (scale bar = 20 μm); B: Quantification of SA-βGal-positive cells expressed as a percentage of the total cell population in PANC1 cultures; C: Representative images of SA-βGal-stained MDA-MB-231 cells after 48 hours of treatment. Blue staining marks SA-βGal-positive senescent cells (scale bar = 20 μm); D: Quantification of SA-βGal-positive cells expressed as a percentage of the total cell population in MDA-MB-231 cultures. Values represent mean ± SD. ^aP ≤ 0.05, ^bP ≤ 0.01, ^cP ≤ 0.001, ^dP ≤ 0.0001. iMSC-Exos: Exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells; BMSC-Exos: Exosomes derived from bone marrow mesenchymal stem cell; SFM: Serum-free medium.